Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

meda ab, pipers vag 2a, box 906, solna, Švedska - kiselina alendronicum, colecalciferolum, carbonas kalcija - filmom obložena tableta + tableta - 70 mg + 500 mg/800 iu - urbroj: tableta alendronata: svaka tableta sadrži 70 mg alendronatne kiseline u obliku natrijevog alendronata trihidrata tableta kalcija/vitamina d3: svaka tableta sadrži 500 mg kalcija u obliku kalcijevog karbonata i 800 iu (20 mikrograma) kolekalciferola (vitamin d3)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - neurotoksin clostridium botulinum tip a (900 kda) - prašak za otopinu za injekciju - 4 allergan jedinice/0,1 ml - urbroj: 1 bočica s praškom za otopinu za injekciju sadrži 50 ili 100 allergan jedinica neurotoksina tipa a (iz bakterije clostridium botulinum) nakon rekonstitucije otopina za injekciju sadržava 4 allergan jedinice u 0,1 ml

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresivi - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ab science - masitinib mesilate - amiotrofna lateralna skleroza - antineoplastična sredstva - liječenje bočnog амиотрофического skleroze.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ab science - masitinib mesilate - mastocitoza - antineoplastična sredstva - liječenje мастоцитоза.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ab science - masitinib - neoplazme gušterače - inhibitori протеинкиназы - liječenje operirati lokalno-uobičajena ili metastaze raka gušterače .

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - brimonidintartarat timololmaleat - kapi za oko, otopina - 2 mg/ml + 5 mg/ml - urbroj: jedan ml otopine sadrži 2,0 mg brimonidintartarata što odgovara 1,3 mg brimonidina i 5,0 mg timolola u obliku timololmaleata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

lobsor pharmaceuticals ab, kalsängsgränd 10 d, uppsala, Švedska - levodopa karbidopa hidrat entakapon - intestinalni gel - urbroj: 1 ml gela sadrži 20 mg levodope, 5 mg karbidopa hidrata i 20 mg entakapona

Europska Unija - hrvatski - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - imunološke za kopitare - konji - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.